statnews.com/2024/04/11/m...@bobjherman.bsky.social@rachelcohrs.bsky.social on CMS's spending projections for lecanemab, which far exceed Eisai's. A good dive into implications for patients, their families, and the health care system.
New Study: We found that 20% of novel small-molecule drugs covered by active non-class-wide REMS have REMS patents, comprising a median 33% of all patents per drug. (with Sajeev Kohli, Sean Tu, and Aaron Kesselheim).
This cross-sectional study identified the prevalence of patents on risk evaluation and mitigation strategies and their association with delaying generic competi
“The U.S. market is the bank for pharmaceutical companies,” said Ameet Sarpatwari, an expert in pharmaceutical policy at Harvard Medical School. “There’s a keen sense that the best place to try to extract profits is the U.S. because of its existing system and its dysfunction.”
Research shows prices in the United States are nearly double those in other well-off countries.
I had a chance to comment in this piece by Sydney Lupkin on @npr.orgwww.npr.org/sections/hea...
Good piece. Remember our collaboration few years ago related to this topic (where is development happening) jamanetwork.com/journals/jam...
I agree with this conclusion. A tilting domino here could have a great rippling effect.
Attention Harvard_Law 1Ls: we are holding an information session for the joint JD/MPH degree program from 12:30-1:30 on November 1 at HLS. It's a great opportunity to earn a dual degree in 3 years. I hope to see you there! hls.harvard.edu/events/harva...
